Upadacitinib in dermatology: A systematic review of mechanism, current applications, efficacy, safety, and emerging evidence
Indian Journal of Dermatology, Venereology and Leprology · 13.10.2025 · 92 · 68-76
DOI: 10.25259/ijdvl_133_2025 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Indian Journal of Dermatology, Venereology and Leprology, online erschienen am 13.10.2025. Verfasst von Sunil Dogra und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India. Hauptthemen laut MEDLINE: Heterocyclic Compounds, 3-Ring, Janus Kinase Inhibitors, Skin Diseases, Dermatitis, Atopic. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 55 Literaturangaben.
Abstract (Originalsprache)
Upadacitinib, a second-generation oral Janus kinase (JAK) inhibitor, selectively targets the JAK 1 non-receptor protein kinase, effectively modulating downstream inflammatory pathways implicated in a range of dermatological diseases. Its JAK 1 selectivity mitigates unwanted side effects associated with broader JAK inhibition. FDA approval for moderate to severe atopic dermatitis (AD) in January 2022 marked a significant milestone, expanding treatment options in dermatology. Since then, upadacitinib has demonstrated efficacy in various dermatological disorders, contributing to improved patient outcomes. This review aims to spotlight its use in AD, as well as off-label indications in dermatology, its safety and efficacy profile, and pertinent information regarding side effects and contraindications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
- Department of Immunopathology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Zitieren
APA
Dogra, S., Prarthana, T., Sudharani, G., & Chhabra, S. (2025). Upadacitinib in dermatology: A systematic review of mechanism, current applications, efficacy, safety, and emerging evidence. Indian Journal of Dermatology, Venereology and Leprology, 92, 68-76. https://doi.org/10.25259/ijdvl_133_2025
Vancouver
Dogra S, Prarthana T, Sudharani G, Chhabra S. Upadacitinib in dermatology: A systematic review of mechanism, current applications, efficacy, safety, and emerging evidence. Indian Journal of Dermatology, Venereology and Leprology. 2025;92:68-76. doi:10.25259/ijdvl_133_2025
BibTeX
@article{Dogra2025,
author = {Dogra, Sunil and Prarthana, Thammannagowda and Sudharani, Gaikwad and Chhabra, Seema},
title = {Upadacitinib in dermatology: A systematic review of mechanism, current applications, efficacy, safety, and emerging evidence},
journal = {Indian Journal of Dermatology, Venereology and Leprology},
year = {2025},
volume = {92},
pages = {68--76},
doi = {10.25259/ijdvl_133_2025}
}
EUVIMED